Interaction Study on Garlic and Atorvastatin with Reference to Nephrotoxicity in Dyslipidaemic Rats
Keywords:
Atorvastatin, garlic, kidneyAbstract
A total of 56 male Sprague dawley rats of uniform weight and age were randomly divided into seven groups consisting of eight rats in each group. Groups 1, 2, and 3 served as plain control, dyslipidaemic control (DL), and atorvastatin control, respectively. Groups 4, 5, 6, and 7 received 1, 0.5, 0.25, and 0.75% fresh garlic w/w in feed, respectively in addition to the high-fat and high-cholesterol diet and administered with atorvastatin orally for 12 weeks at the rate of 10, 5, 7.5, and 2.5 mg/kg b.wt., respectively. Plasma creatinine was estimated at 4-week intervals, whereas histopathology, electron microscopy, and estimation of TBARS concentration in kidney were conducted at the end of experiment. The TBARS concentration in DL was significantly (P<0.05) increased when compared with groups 1, 3, 6, and 7. On histopathological examination, kidney sections of group 3 had mild degenerative changes in the tubules with fatty change in few tubules, while groups 4 and 5 exhibited mild-tomoderate degenerative and fatty changes in tubules with inter tubular hemorrhages. The electron microscopy of group 2 showed hypertrophy of Bowman's capsule, while that of group 4 showed secretary deposits in the cytoplasm. The interaction studies on kidney indicated that high dose of atorvastatin + garlic has negative safety profile when compared with groups having low dose of statin and high dose of garlic.Downloads
Published
How to Cite
Issue
Section
Accepted 2018-05-15
Published 2018-05-16
References
Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. NewYork: McGraw Hill; 2006. p. 933-60.
Malhotra HS, Goa KL. Atorvastatin: An updated review of its pharmacological properties and use in dyslipidaemia. Drug evaluation. Drugs 2001;61:1835-81.
Alaupovic P, Heinonen T, Shurzinske L, Black DM. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis 1997;133:123-33.
Dubey NK, Kumar R, Tripathi P. Global promotion of herbal medicine: India's opportunity. Curr Sci 2004;86:37-41.
Lau BH, Adetumbi MA, Sanchez A. Allium sativum (garlic) and atherosclerosis: A review. Nutr Res 1983;3:119-28.
Chi MS, Koh ET, Stewartt AJ. Effects of garlic on lipid metabolism in rats fed cholesterol or lard. J Nutr 1982;112:241-8.
Jani A, Mehta A. Pharmacology of Allium sativum in relation to Cytochrome P450 and possible drug interactions. Pharmacogn Rev 2007;2:222-6.
Balasubramanian KA, Manohar M, Mathan VI. An unidentified inhibitor of lipid peroxidation in intestinal mucosa. Biochim Biophys Acta 1988;962:51-8.
Culling CF. Handbook of Histopathological and Histochemical Techniques. 3rd ed. London, U.K.: Butterworths and Co.; 1974.
Bozzola JJ, Russell LD. Electron microscopy: Principles and techniques for biologists. 2nd ed. Boston: Jones and Bartlett; 1999.
Kaneko JJ, Harvey JW, Michael LB. Clinical Biochemistry of Domestic Animals. 5th ed. New York: Academic press; 1997. p. 182-9, 857-79.
Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmaceutical Sci 2001;4:159-67.
Pedraza-Chaverri J, Yam-Canul P, Chirino YI, Sánchez-González DJ, Martínez-Martínez CM, Cruz C, et al. Protective effects of garlic powder against potassium dichromate-induced oxidative stress and nephrotoxicity. Food Chem Toxicol 2008;46:619-27.
Segoviano-Murillo S, Sánchez-González DJ, Martínez-Martínez CM, Cruz C, Maldonado PD, Pedraza-Chaverrí J. S-allylcysteine ameliorates ischemia and reperfusion induced renal damage. Phytother Res 2007;22:836-40.